---
title: "Stelara (ustekinumab) in plaque psoriasis: Pharmacology questions"
description: "Pharmacology questions on Stelara (ustekinumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pharmacokinetics and Components. Questions: How long does Stelara stay in your system (half-life)? When does Stelara reach peak and steady-state levels in plaque psoriasis? Does body weight affect Stelara blood levels in psoriasis? What are the inactive ingredients in Stelara? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/pharmacology"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Stelara (ustekinumab) in plaque psoriasis: Pharmacology questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Stelara](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf)

Pharmacology questions that apply to every indication of Stelara are on [Stelara (ustekinumab), all indications: Pharmacology](https://www.evicenter.com/medical-information/stelara/pharmacology).

## Pharmacokinetics

<a id="stelara-half-life"></a>

### How long does Stelara stay in your system (half-life)?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “The mean (±SD) half-life ranged from 14.9 ± 4.6 to 45.6 ± 80.2 days across all 
> trials in subjects with plaque psoriasis following subcutaneous administration.”

Source: [STELARA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=7)

<a id="stelara-absorption"></a>

### When does Stelara reach peak and steady-state levels in plaque psoriasis?

> “In adult subjects with plaque psoriasis, the median time to reach the maximum 
> serum concentration (Tmax) was 13.5 days and 7 days, respectively, after a single 
> subcutaneous administration of 45 mg (N=22) and 90 mg (N=24) of ustekinumab. 
> In healthy subjects (N=30), the median Tmax value (8.5 days) following a single 
> subcutaneous administration of 90 mg of ustekinumab was comparable to that 
> observed in subjects with plaque psoriasis.
> Following multiple subcutaneous doses of STELARA in adult subjects with plaque 
> psoriasis, steady-state serum concentrations of ustekinumab were achieved by 
> Week 28. The mean (±SD) steady-state trough serum ustekinumab concentrations 
> were 0.69 ± 0.69 mcg/mL for subjects less than or equal to 100 kg receiving a 
> 45 mg dose and 0.74 ± 0.78 mcg/mL for subjects greater than 100 kg receiving 
> a 90 mg dose. There was no apparent accumulation in serum ustekinumab 
> concentration over time when given subcutaneously every 12 weeks.”

Source: [STELARA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=7)

> “Following multiple recommended doses of STELARA in pediatric subjects 
> 6 years of age and older with plaque psoriasis, steady-state serum concentrations 
> of ustekinumab were achieved by Week 28.”

Source: [STELARA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=7)

<a id="stelara-body-weight-levels"></a>

### Does body weight affect Stelara blood levels in psoriasis?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “When given the same dose, subjects with plaque psoriasis or psoriatic arthritis 
> weighing more than 100 kg had lower median serum ustekinumab concentrations 
> compared with those subjects weighing 100 kg or less. The median trough serum 
> concentrations of ustekinumab in subjects of higher weight (greater than 100 kg) 
> in the 90 mg group were comparable to those in subjects of lower weight (100 kg 
> or less) in the 45 mg group.”

Source: [STELARA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=7)

## Components

<a id="stelara-inactive-ingredients"></a>

### What are the inactive ingredients in Stelara?

> “STELARA<sup>®</sup> (ustekinumab) injection is a sterile, preservative-free, colorless to light 
> yellow solution and may contain a few small translucent or white particles with 
> pH of 5.7-6.3.”

Source: [STELARA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=7)

> “Each 0.5 mL prefilled syringe or vial delivers 45 mg ustekinumab, L-histidine and 
> L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), 
> and sucrose (38 mg).
> Each 1 mL prefilled syringe delivers 90 mg ustekinumab, L-histidine and L-histidine 
> monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg).”

Source: [STELARA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=7)

Note: The subcutaneous presentations used for plaque psoriasis are quoted; the label lists a separate composition for the intravenous vial used in Crohn's disease and ulcerative colitis.

## Related pages
- [Medical information: Stelara (ustekinumab): Plaque psoriasis](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/storage-and-supply)
